Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Institute of Medical Genetics, Tomsk National Research Medical Center, 634009 Tomsk, Russia.
Int J Mol Sci. 2022 Mar 4;23(5):2835. doi: 10.3390/ijms23052835.
Although half of hypertensive patients have hypertensive parents, known hypertension-related human loci identified by genome-wide analysis explain only 3% of hypertension heredity. Therefore, mainstream transcriptome profiling of hypertensive subjects addresses differentially expressed genes (DEGs) specific to gender, age, and comorbidities in accordance with predictive preventive personalized participatory medicine treating patients according to their symptoms, individual lifestyle, and genetic background. Within this mainstream paradigm, here, we determined whether, among the known hypertension-related DEGs that we could find, there is any genome-wide hypertension theranostic molecular marker applicable to everyone, everywhere, anytime. Therefore, we sequenced the hippocampal transcriptome of tame and aggressive rats, corresponding to low and high stress reactivity, an increase of which raises hypertensive risk; we identified stress-reactivity-related rat DEGs and compared them with their known homologous hypertension-related animal DEGs. This yielded significant correlations between stress reactivity-related and hypertension-related fold changes (log2 values) of these DEG homologs. We found principal components, PC1 and PC2, corresponding to a half-difference and half-sum of these log2 values. Using the DEGs of hypertensive versus normotensive patients (as the control), we verified the correlations and principal components. This analysis highlighted downregulation of β-protocadherins and hemoglobin as whole-genome hypertension theranostic molecular markers associated with a wide vascular inner diameter and low blood viscosity, respectively.
尽管一半的高血压患者有高血压的父母,但通过全基因组分析确定的与高血压相关的已知人类基因座仅能解释 3%的高血压遗传。因此,主流的高血压患者转录组分析针对性别、年龄和合并症等因素,根据预测性、预防性、个体化和参与性医学,根据患者的症状、个人生活方式和遗传背景进行治疗。在这个主流范式中,我们在这里确定,在我们能找到的已知与高血压相关的差异表达基因(DEGs)中,是否有任何适用于所有人、任何时间、任何地点的全基因组高血压治疗的分子标记物。因此,我们对温顺和攻击性大鼠的海马转录组进行了测序,这些大鼠对应于低和高应激反应,应激反应的增加会增加高血压的风险;我们确定了与应激反应相关的大鼠 DEGs,并将其与已知的与高血压相关的动物 DEGs 进行了比较。这产生了这些 DEG 同源物的应激反应相关和高血压相关折叠变化(log2 值)之间的显著相关性。我们发现了与这些 log2 值的一半差异和一半总和相对应的主成分 PC1 和 PC2。使用高血压与正常血压患者的 DEGs(作为对照),我们验证了相关性和主成分。该分析强调了β原钙黏蛋白和血红蛋白的下调,作为与全基因组高血压治疗相关的分子标记物,分别与广泛的血管内直径和低血液粘度相关。
Int J Mol Sci. 2023-2-16
Mol Biol (Mosk). 2023
PLoS One. 2017-9-7
Clin Exp Hypertens. 2018-2-5
Int J Mol Sci. 2023-2-16
Zhonghua Yu Fang Yi Xue Za Zhi. 2021-12-6
Hypertens Res. 2022-2
Tokai J Exp Clin Med. 2021-12-20